Rafael Williams, MD
Orthopaedic Surgery · Wilson, WYNPI 1225067606
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (47.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Arthrex at 52.4% of the total. Reporting peaked in 2022 at $4,141 and has fallen 83.7% since, to $676 in 2025.
Across 67 payments — averaging $142.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$5K
- Smith+Nephew$2K
- Active Medical, LLC$2K
- Anika Therapeutics, Inc.$193
- Arthrosurface Incorporated$100
- Johnson & Johnson$39
- plus $22 from 2 others
What the payments were for
- Speaking & faculty fees$1,00010%
- Travel & lodging$4,50447%
- Food & beverage$2,71328%
- Education$1,35014%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 34 | $5,017 |
| Smith+Nephew | 21 | $2,150 |
| Active Medical, LLC | 5 | $2,045 |
| Anika Therapeutics, Inc. | 2 | $193 |
| Arthrosurface Incorporated | 1 | $100 |
| Johnson & Johnson | 2 | $39 |
| Pfizer | 1 | $11 |
| Ossio Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Latarjet System$1,066
- Q-FIX$1,066
- Regeneten$323
- MULTIFIX S$219
- OVOMotion$120
- Bioinductive Implant with Arthroscopic Delivery System - Medium$105
- Coblation Wands$104
- HemiCAP Wrist$100
How this compares
$9,567 in reported general payments places this provider in the 85th percentile of 69 orthopaedic surgery providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 95 | $2,404 |
| Ondansetron OdtOndansetron | 102 | $851 |
| Clindamycin Phos-Benzoyl PeroxClindamycin Phos/Benzoyl Perox | 21 | $453 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 51 | $285 |
| Cyclobenzaprine Hcl | 84 | $284 |
| Oxycodone Hcl | 75 | $192 |
| Mupirocin | 15 | $116 |
| Tramadol Hcl | 36 | $115 |
| Meloxicam | 18 | $107 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Wilson
- Christopher HillsJackson$107K
- Matthew FournierLaramie$34K
- Jaymeson ArthurCasper$30K
- Ryan AukermanLaramie$24K
- Robert GrunfeldGillette$17K
- Mark RyzewiczCody$14K
- Jory WasserburgerSheridan$12K
- Mark McKennaLaramie$10K
- Emily HarndenCody$9K
- Stanford IsraelsenGillette$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.